Sargramostim plus Ipilimumab vs Ipilimumab Alone for Treatment of Metastatic Melanoma: A Randomized Clinical Trial

IMPORTANCE: Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade with ipilimumab prolongs survival in metastatic melanoma patients. CTLA-4 blockade and granulocyte-macrophage colony stimulating factor (GM-CSF) secreting tumor vaccine combinations demonstrate therapeutic synergy in pre-clini...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JAMA
Auteurs principaux: Hodi, F. Stephen, Lee, Sandra, McDermott, David F., Rao, Uma N., Butterfield, Lisa H., Tarhini, Ahmad A., Leming, Philip, Puzanov, Igor, Shin, Donghoon, Kirkwood, John M.
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4336189/
https://ncbi.nlm.nih.gov/pubmed/25369488
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jama.2014.13943
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires